Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
377 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06861530 | A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children(LeukemiaCort) | recruiting | — | 40 | University Children's Hospital BaselOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03819101 | Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer(PEACE-4) | recruiting | Phase 3 | 1,210 | Gustave Roussy, Cancer Campus, Grand Paris |
| 6 |
| May 6, 2026 |
| clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT06794372 | [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas(FAPIHN) | recruiting | Phase 2 | 20 | John O. PriorOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06936774 | Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance(iRECOVER) | recruiting | Phase 3 | 140 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT06249672 | Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy(PRESERVE) | recruiting | — | 200 | Insel Gruppe AG, University Hospital BernOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06466382 | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy(OVPrecision) | recruiting | N/A | 60 | Swiss GO Trial GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT07378423 | Questionnaire on Congenital Cancer Signs Through Self-Assessment(QUOCCAS) | recruiting | N/A | 205 | Insel Gruppe AG, University Hospital BernOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07173127 | The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters | recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)(GETUG-AFU 40) | recruiting | Phase 3 | 300 | UNICANCEROTHER | 12 | Apr 28, 2026 | clinicaltrials |
| NCT06852313 | Save the Ovaries - Surgical Management of Simple Ovarian Cysts in Children and Adolescents | recruiting | N/A | 80 | University Children's Hospital, ZurichOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT06205953 | A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)(EUREKA) | recruiting | — | 400 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 6 | Apr 16, 2026 | clinicaltrials |
| NCT07020065 | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | recruiting | Phase 2 | 156 | Swiss Cancer InstituteOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05120596 | First in Human Study of T3P-Y058-739 (T3P) | recruiting | Phase 1 / Phase 2 | 100 | T3 Pharmaceuticals AGINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06114108 | Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients(salVage) | recruiting | N/A | 128 | Swiss Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07481890 | Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. | recruiting | N/A | 46 | Lega Cancro TicinoOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07494864 | Effects of Microbiological and Immunological Factors on the Lower Urinary Tract(MiLUT) | recruiting | — | 800 | University of ZurichOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT07355374 | Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE(WIDE) | recruiting | N/A | 116 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT06352710 | Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment | recruiting | — | 400 | Cantonal Hospital of St. GallenOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483112 | Fiber-Boost Randomized Controlled Trial(Fiber-Boost) | recruiting | N/A | 42 | Cantonal Hospital of St. GallenOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06787014 | Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study(ENETSSurgSmInt) | recruiting | — | 3,200 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07472972 | Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0) | recruiting | — | 50 | University of ZurichOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT02280889 | Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision | recruiting | — | 100 | University Children's Hospital, ZurichOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05124236 | Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases(PREOP-2) | recruiting | N/A | 200 | Susanne RogersOTHER | 3 | Mar 4, 2026 | clinicaltrials |
| NCT07302919 | Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma(IMPACT-TACE) | recruiting | Phase 2 / Phase 3 | 152 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT03463954 | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | recruiting | N/A | 122 | Novian Health Inc.INDUSTRY | 5 | Feb 19, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07397715 | Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms(MUSA3) | recruiting | — | 1,000 | Swiss GO Trial GroupNETWORK | 3 | Feb 12, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT06855784 | Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)(TREMHO) | recruiting | N/A | 84 | University Hospital, GenevaOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT06712459 | Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma | recruiting | — | 100 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 7 | Jan 16, 2026 | clinicaltrials |
| NCT02229916 | Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS(SAG TCCS) | recruiting | — | 6,900 | Dr. med. Christian RothermundtOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07319039 | Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study(BREACH-fMRI) | recruiting | — | 16 | University Hospital, GenevaOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05717166 | A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.(SABR-SYNC) | recruiting | Phase 3 | 180 | David PalmaOTHER | 2 | Dec 31, 2025 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT06452394 | NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline | recruiting | Phase 2 | 50 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06835049 | Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)(TNT-HYPE) | recruiting | Phase 2 | 24 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07309497 | Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)(GA-ACT) | recruiting | — | 208 | University of ZurichOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06479070 | Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.(CIRADOR) | recruiting | N/A | 188 | Institut de Cancérologie de LorraineOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07189117 | Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies | recruiting | — | 350 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07171658 | Breast Cancer-Related Approach for Increasing Cervical Cancer Screening(BRAICS) | recruiting | N/A | 4,500 | Jessica Di Vincenzo SormaniOTHER | 1 | Dec 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials